Archives: 2022-05-21

‘Cell pores’ discovery and a new drug give hope to millions of brain and spinal cord injury patients

Scientists from the University of Birmingham have shown an existing drug may reduce damage after spinal cord injury, by blocking the inflammatory response in the spinal cord. Their research, published today in Clinical and Translational Medicine, demonstrates that AZD1236, a drug developed by AstraZeneca, can significantly reduce “secondary damage” caused by the body’s response to spinal

Read More


Amyloid production induced by neutrophil elastase as possible mechanism behind enigmatic symptoms in Severe Covid-19

In severe covid-19 and long-term covid, disorders of blood coagulation often occur. Now, researchers at LiU have discovered that the body’s immune system can affect the nail protein on the surface of the sars-cov-2 virus so that it forms misfolded protein, so-called amyloid. The findings point to a possible link between harmful amyloid formation and covid-19 symptoms.

Read More


BWH Scientists Develop ‘Off the Shelf’ Engineered Stem Cells to Treat Aggressive Glioblastoma

Glioblastomas (GBMs) are highly aggressive cancerous tumors of the brain and spinal cord. Brain cancers like GBM are challenging to treat because many cancer therapeutics cannot pass through the blood-brain barrier, and more than 90 percent of GBM tumors return after being surgically removed, despite surgery and subsequent chemo- and radiation therapy being the most

Read More


University of Minnesota technology allows amputees to control a robotic arm with their mind

Research team makes mind-reading possible with electronics and AI University of Minnesota Twin Cities researchers have developed a more accurate, less invasive technology that allows amputees to move a robotic arm using their brain signals instead of their muscles.  Many current commercial prosthetic limbs use a cable and harness system that is controlled by the

Read More


90-Day Clinical Outcome of Critically Ill Hospitalized Covid-19 Patients Treated with Imatinib: lower mortality rate, shorter duration of invasive ventilation and more ventilator free days.

Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference. The study investigated the long-term efficacy of imatinib in hospitalized COVID-19 patients in the Netherlands as part of the randomized, double-blind, placebo-controlled CounterCOVID study. A tyrosine kinase inhibitor, imatinib is currently an oncology

Read More


Identifying who has long COVID in the USA: a machine learning approach using N3C data

Using machine learning, researchers find patterns in electronic health record data to better identify those likely to have the condition. Long COVID is marked by wide-ranging symptoms, including shortness of breath, fatigue, fever, headaches, “brain fog” and other neurological problems. Such symptoms can last for many months or longer after an initial COVID-19 diagnosis. One

Read More


SARS-CoV-2 superantigens could be involved in Severe acute pediatric hepatitis, following a letter on The Lancet Gastroenterology & Hepatology

Recently, there have been reports of children with a severe acute form of hepatitis in the UK, Europe, the USA, Israel, and Japan.  Most patients present with gastrointestinal symptoms and then progress to jaundice and, in some cases, acute liver failure. So far, no common environmental exposures have been found, and an infectious agent remains

Read More


New type of cell therapy can repair damaged heart tissue after infarction

Researchers at Karolinska Institutet, Technical University of Munich (TUM) in Germany and AstraZeneca, among others, have identified a new type of cell therapy with the potential to heal injuries to the heart after a heart attack. The preclinical study, published in the journal Nature Cell Biology, shows that so-called ventricular progenitor cells can stimulate the heart’s

Read More